SK Biopharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

SK Biopharmaceuticals heeft een totaal eigen vermogen van ₩366.3B en een totale schuld van ₩145.5B, wat de schuld-eigenvermogensverhouding op 39.7% brengt. De totale activa en totale passiva bedragen respectievelijk ₩775.0B en ₩408.8B. De EBIT SK Biopharmaceuticals is ₩70.5B waardoor de rentedekking -1200.3 is. Het heeft contanten en kortetermijnbeleggingen van ₩267.5B.

Belangrijke informatie

39.7%

Verhouding schuld/eigen vermogen

₩145.53b

Schuld

Rente dekkingsratio	-1200.3x
Contant	₩267.54b
Aandelen	₩366.26b
Totaal verplichtingen	₩408.76b
Totaal activa	₩775.02b

Recente financiële gezondheidsupdates

Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?

Feb 27

We're Not Worried About SK Biopharmaceuticals' (KRX:326030) Cash Burn

Mar 12

Recent updates

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Shares Could Be 47% Below Their Intrinsic Value Estimate

Nov 27

There May Be Underlying Issues With The Quality Of SK Biopharmaceuticals' (KRX:326030) Earnings

Aug 22

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Looks Just Right With A 25% Price Jump

Aug 21

Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?

May 22

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing

Apr 09

Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?

Feb 27

We're Not Worried About SK Biopharmaceuticals' (KRX:326030) Cash Burn

Mar 12

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₩551.5B ) A326030 } overtreffen de korte termijn passiva ( ₩338.5B ).

Langlopende schulden: De kortetermijnactiva A326030 ( ₩551.5B ) overtreffen de langetermijnschulden ( ₩70.3B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: A326030 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van A326030 is de afgelopen 5 jaar gedaald van 1619.8% naar 39.7%.

Schuldendekking: De schuld van A326030 wordt niet goed gedekt door de operationele kasstroom ( 13.6% ).

Rentedekking: A326030 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

SK Biopharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?

We're Not Worried About SK Biopharmaceuticals' (KRX:326030) Cash Burn

Recent updates

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Shares Could Be 47% Below Their Intrinsic Value Estimate

New major risk - Earnings quality

Consensus EPS estimates increase by 13%

There May Be Underlying Issues With The Quality Of SK Biopharmaceuticals' (KRX:326030) Earnings

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Looks Just Right With A 25% Price Jump

Now 22% overvalued

Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?

SK Biopharmaceuticals Co., Ltd. to Report Q1, 2024 Results on May 09, 2024

SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing

Full year 2023 earnings released: ₩420 loss per share (vs ₩1,780 loss in FY 2022)

Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?

SK Biopharmaceuticals Co., Ltd. to Report Q4, 2023 Results on Jan 29, 2024

Consensus EPS estimates upgraded to ₩604 loss, revenue downgraded

SK Biopharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Nov 09, 2023

SK Biopharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Nov 09, 2023

Consensus EPS estimates fall by 11%

SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sk Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and Moped Molecular Glue Screening Platform At the 20Th Annual Discovery on Target Conference

Consensus EPS estimates fall by 14%

Price target increased by 9.2% to ₩105,308

SK Biopharmaceuticals Assembles Board of Prominent Experts to Boost Growth, Innovation

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 19%

Consensus estimates of losses per share improve by 17%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Now 21% undervalued

Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device At AES 2022

SK Biopharmaceuticals Appoints Donghoon Lee as President of Company and U.S. Subsidiary Effective January 1, 2023

SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969

Consensus estimates of losses per share improve by 12%

Consensus forecasts updated

Consensus forecasts updated

High number of new and inexperienced directors

Price target decreased to ₩110,167

Price target decreased to ₩108,200

Consensus revenue estimates fall by 16%

Price target decreased to ₩119,750

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Consensus EPS estimates have been upgraded.

No longer forecast to breakeven

Third quarter 2021 earnings released: ₩565 loss per share (vs ₩850 loss in 3Q 2020)

Forecast breakeven moved forward to 2022

Consensus EPS estimates increase to -₩2.68

Consensus forecasts updated

Consensus forecasts updated

Consensus EPS estimates increase to -₩608

We're Not Worried About SK Biopharmaceuticals' (KRX:326030) Cash Burn

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven